Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial

Reznik, Yves; Cohen, Ohad; Aronson, Ronnie; Conget, Ignacio; Runzis, Sarah; Castañeda, Javier; Lee, Scott W.

doi:10.1016/s0140-6736(14)61037-0

Cited by 180 publications

(232 citation statements)

References 20 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…Recent studies 11,12,19,20,34,35 , provide an optimistic outlook on perspectives for advanced technologies for the treatment of diabetes.…”

Section: Discussionmentioning

confidence: 99%

Glucose concentrations in blood and tissue - a pilot study on variable time lag

Chlup¹,

Krejčí²,

O’Connell³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

Aim. The aim of this pilot study was to acquire insight into the parameters of glycaemic control, especially, (1) the time delay (lag phase) between plasma and tissue glucose concentrations in relation to rise and fall in glucose levels and (2) the rate of glucose increase and decrease. Methods. Four healthy people (HP), 4 people with type 1diabetes (DM1) and 4 with type 2 diabetes (DM2) underwent concurrent glucose measurements by means of (1) the continuous glucose monitoring system (CGMS-Medtronic), Medtronic-Minimed, CA, USA, calibrated by the glucometer Calla, Wellion, Austria, and, (2) the Beckman II analyser to measure glucose concentrations in venous plasma. Samples were taken on 4 consecutive days in the fasting state and 4 times after consumption of 50 g glucose. Carelink Personal, MS Excel, Maple and Mat lab were applied to plot the evolution of glucose concentration and analyse the results. The time difference between increase and decrease was calculated for HP, DM 1 and DM 2. Results. In DM1and DM2, glucose tolerance testing (GTT) resulted in slower transport of glucose into subcutaneous tissue than in HP where the lag phase lasted up to 12 min. The maximum increase/decrease rates in DM1 and DM2 vs HP were 0.25 vs < 0.1 mmol/L/min. Conclusion. CGMS is shown to provide reliable plasma glucose concentrations provided the system is calibrated during a steady state. The analysis of glucose change rates improves understanding of metabolic processes better than standard GTT.

show abstract

“…Recent studies 11,12,19,20,34,35 , provide an optimistic outlook on perspectives for advanced technologies for the treatment of diabetes.…”

Section: Discussionmentioning

confidence: 99%

Glucose concentrations in blood and tissue - a pilot study on variable time lag

Chlup¹,

Krejčí²,

O’Connell³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…A less commonly used and more costly alternative to "basal-bolus" therapy with multiple daily injections is CSII (insulin pump) (28,29). In addition to the suggestions provided for determining the starting dose of mealtime insulin under a basal-bolus regimen, another method consists of adding up the total current insulin dose and then providing one-half of this amount as basal and one-half as mealtime insulin, the latter split evenly between three meals.…”

Section: Continuous Subcutaneous Insulin Infusionmentioning

confidence: 99%

7. Approaches to Glycemic Treatment

2015

Diabetes Care

202

117

View full text Add to dashboard Cite

“…However, as the emergence of clinical evidence can be fluid and dynamic, the omission of significant new findings from very recent studies might occur. This occurred with the present article as concurrent with its publication a late-breaking study on the use of continuous subcutaneous insulin infusion (CSII) in people with type 2 diabetes was presented at the American Diabetes Association 2014 Scientific Sessions in San Francisco and recently published online in The Lancet (2). This OpT2mise study reports the results of a large randomized controlled study comparing patients on multiple daily insulin injections (MDI) using insulin analogs to patients on CSII therapy who were previously unable to reach glycated hemoglobin (HbA 1c ) targets using intensified therapy with MDI regimen.…”

mentioning

confidence: 85%